PDF herunterladen
Semin Thromb Hemost 2015; 41(06): 556-562
DOI: 10.1055/s-0035-1556587
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombosis, Microangiopathies, and Inflammation

Karen Matevosyan
1   Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, Dallas, Texas
,
Ravi Sarode
1   Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, Dallas, Texas
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. August 2015 (online)

    Lizenzen und Reprints

Abstract

Thrombotic microangiopathy (TMA) is characterized by the presence of microangiopathic hemolytic anemia and thrombocytopenia. There are several disorders with varied etiopathogenesis, both genetic and acquired, that result in TMA. The neutrophils play an important role in inflammation and thrombosis through the formation of neutrophil extracellular traps (NETs). NETs are formed in response to a variety of stimuli including infections, chemical factors, and platelet activation. The classic TMA, thrombotic thrombocytopenic purpura (TTP) is caused by a severe deficiency of ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type-I motif, member 13), mostly acquired due to autoantibodies, whereas atypical hemolytic uremic syndrome (aHUS) is mostly attributed to genetic defects in complement pathway regulatory proteins. The management of these well-known disorders has evolved over the last decade. Similarly, there is also better understanding of diverse and unusual clinical presentations of both of these conditions. Since there are many other causes of TMAs, which may mimic some of the clinical features of TTP or aHUS, it is essential to thoroughly investigate each patient so that appropriate therapy can be offered. This review focuses on some important developments in understanding of etiopathogenesis, diagnosis, and treatment of more commonly encountered TMAs.

Keywords

ADAMTS-13 - complement - endothelium - hemolytic uremic syndrome - neutrophils - microangiopathic hemolytic anemia - thrombocytopenia - thrombotic microangiopathy - thrombotic thrombocytopenic purpura
 

  • References

  • 1 Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012; 38 (5) 469-482
    Thieme ConnectPubMedSuche in Google Scholar
  • 2 Zawrotniak M, Rapala-Kozik M. Neutrophil extracellular traps (NETs) - formation and implications. Acta Biochim Pol 2013; 60 (3) 277-284
    PubMedSuche in Google Scholar
  • 3 Fuchs TA, Brill A, Duerschmied D , et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
    CrossrefPubMedSuche in Google Scholar
  • 4 Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297 (25) 1386-1389
    CrossrefPubMedSuche in Google Scholar
  • 5 Moake JL, Rudy CK, Troll JH , et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
    CrossrefPubMedSuche in Google Scholar
  • 6 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
    CrossrefPubMedSuche in Google Scholar
  • 7 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
    CrossrefPubMedSuche in Google Scholar
  • 8 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91 (8) 2839-2846
    PubMedSuche in Google Scholar
  • 9 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
    CrossrefPubMedSuche in Google Scholar
  • 10 Rock GA, Shumak KH, Buskard NA , et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325 (6) 393-397
    CrossrefPubMedSuche in Google Scholar
  • 11 Levy GG, Nichols WC, Lian EC , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855) 488-494
    CrossrefPubMedSuche in Google Scholar
  • 12 Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159 (21) 2524-2528
    CrossrefPubMedSuche in Google Scholar
  • 13 Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132 (10) 794-799
    PubMedSuche in Google Scholar
  • 14 Widemann A, Pasero C, Arnaud L , et al. Circulating endothelial cells and progenitors as prognostic factors during auto-immune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study. J Thromb Haemost 2014; 12 (10) 1601-1609
    CrossrefPubMedSuche in Google Scholar
  • 15 Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012; 120 (6) 1157-1164
    CrossrefPubMedSuche in Google Scholar
  • 16 Réti M, Farkas P, Csuka D , et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10 (5) 791-798
    CrossrefPubMedSuche in Google Scholar
  • 17 Ruiz-Torres MP, Casiraghi F, Galbusera M , et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93 (3) 443-452
    PubMedSuche in Google Scholar
  • 18 Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 2014; 40 (5) 544-550
    Thieme ConnectPubMedSuche in Google Scholar
  • 19 George JN, Chen Q, Deford CC, Al-Nouri Z. Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency. J Clin Apher 2012; 27 (6) 302-311
    CrossrefPubMedSuche in Google Scholar
  • 20 Sarode R, Bandarenko N, Brecher ME , et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29 (3) 148-167
    CrossrefPubMedSuche in Google Scholar
  • 21 Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher 2004; 19 (2) 86-89
    CrossrefPubMedSuche in Google Scholar
  • 22 Rojas JC, Banerjee C, Siddiqui F, Nourbakhsh B, Powell CM. Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology 2013; 80 (22) e235-e238
    CrossrefPubMedSuche in Google Scholar
  • 23 Idowu M, Reddy P. Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke. Am J Hematol 2013; 88 (3) 237-239
    CrossrefPubMedSuche in Google Scholar
  • 24 Cataland SR, Scully MA, Paskavitz J , et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86 (1) 87-89
    CrossrefPubMedSuche in Google Scholar
  • 25 Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2013; 163 (4) 514-519
    CrossrefPubMedSuche in Google Scholar
  • 26 Tripodi A, Peyvandi F, Chantarangkul V , et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6 (9) 1534-1541
    CrossrefPubMedSuche in Google Scholar
  • 27 Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8 (4) 631-640
    CrossrefPubMedSuche in Google Scholar
  • 28 Wu HM, Cataland SR, Bissell M, Jin M. Application of SELDI-TOF mass spectrometry in clinical evaluation of thrombotic thrombocytopenic purpura. Spectroscopy 2006; 20 (5–6) 219-227
    CrossrefPubMedSuche in Google Scholar
  • 29 Beloncle F, Buffet M, Coindre JP , et al; Thrombotic Microangiopathies Reference Center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52 (11) 2436-2444
    CrossrefPubMedSuche in Google Scholar
  • 30 Cataland SR, Jin M, Ferketich AK , et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136 (1) 146-149
    CrossrefPubMedSuche in Google Scholar
  • 31 Froissart A, Buffet M, Veyradier A , et al; French Thrombotic Microangiopathies Reference Center. Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med 2012; 40 (1) 104-111
    CrossrefPubMedSuche in Google Scholar
  • 32 Goyal J, Adamski J, Lima JL, Marques MB. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab. J Clin Apher 2013; 28 (6) 390-394
    CrossrefPubMedSuche in Google Scholar
  • 33 Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013; 368 (1) 90-92
    CrossrefPubMedSuche in Google Scholar
  • 34 van Balen T, Schreuder MF, de Jong H, van de Kar NC. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 2014; 92 (1) 80-82
    CrossrefPubMedSuche in Google Scholar
  • 35 Yates S, Matevosyan K, Rutherford C, Shen YM, Sarode R. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 2014; 54 (8) 2064-2067
    CrossrefPubMedSuche in Google Scholar
  • 36 Chen J, Reheman A, Gushiken FC , et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121 (2) 593-603
    CrossrefPubMedSuche in Google Scholar
  • 37 Li GW, Rambally S, Kamboj J , et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion 2014; 54 (5) 1221-1224
    CrossrefPubMedSuche in Google Scholar
  • 38 Ulrichts H, Silence K, Schoolmeester A , et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011; 118 (3) 757-765
    CrossrefPubMedSuche in Google Scholar
  • 39 Results of the TITAN study for Caplacizumab. In Ablynx. Webcast presentation. June 17, 2014. Available at: http://www.ablynx.com/uploads/data/files/webcast-titan-_17-june-2014.pdf . Accessed June 17, 2014
    PubMed
  • 40 Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knöbl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105 (3) 545-552
    PubMedSuche in Google Scholar
  • 41 Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 106 (3) 539-547
    Thieme ConnectPubMedSuche in Google Scholar
  • 42 George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371 (7) 654-666
    CrossrefPubMedSuche in Google Scholar
  • 43 Dragon-Durey MA, Blanc C, Marliot F , et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46 (7) 447-450
    CrossrefPubMedSuche in Google Scholar
  • 44 Bienaime F, Dragon-Durey MA, Regnier CH , et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010; 77 (4) 339-349
    CrossrefPubMedSuche in Google Scholar
  • 45 Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8 (5) 286-293
    CrossrefPubMedSuche in Google Scholar
  • 46 Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial 2004; 8 (2) 102-111
    CrossrefPubMedSuche in Google Scholar
  • 47 Gottschall JL, Neahring B, McFarland JG, Wu GG, Weitekamp LA, Aster RH. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994; 47 (4) 283-289
    CrossrefPubMedSuche in Google Scholar
  • 48 Saif MW, Xyla V, Makrilia N, Bliziotis I, Syrigos K. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 2009; 8 (3) 257-260
    CrossrefPubMedSuche in Google Scholar
  • 49 Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007; 19 (2) 148-154
    CrossrefPubMedSuche in Google Scholar
  • 50 Al-Akash SI, Almond PS, Savell Jr VH, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26 (4) 613-619
    CrossrefPubMedSuche in Google Scholar
  • 51 Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013; 166 (2) 117-123
    CrossrefPubMedSuche in Google Scholar
  • 52 Johal T, Lees CC, Everett TR, Wilkinson IB. The nitric oxide pathway and possible therapeutic options in pre-eclampsia. Br J Clin Pharmacol 2014; 78 (2) 244-257
    CrossrefPubMedSuche in Google Scholar
  • 53 Derzsy Z, Prohászka Z, Rigó Jr J, Füst G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47 (7-8) 1500-1506
    CrossrefPubMedSuche in Google Scholar
  • 54 Pourrat O, Coudroy R, Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol 2013; 163 (3) 409-410
    CrossrefPubMedSuche in Google Scholar
  • 55 Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013; 34 (2) 201-203
    CrossrefPubMedSuche in Google Scholar
  • 56 Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R ; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum 2013; 42 (4) 417-423
    CrossrefPubMedSuche in Google Scholar
  • 57 De Simone N, Racsa L, Bevan S , et al. Therapeutic plasma exchange in the management of sepsis and multiple organ dysfunction syndrome: a report of three cases. J Clin Apher 2014; 29 (2) 127-131
    CrossrefPubMedSuche in Google Scholar
  • 58 Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348 (16) 1546-1554
    CrossrefPubMedSuche in Google Scholar
  • 59 Nguyen TC, Liu A, Liu L , et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92 (1) 121-124
    CrossrefPubMedSuche in Google Scholar
  • 60 Martin K, Borgel D, Lerolle N , et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35 (10) 2375-2382
    CrossrefPubMedSuche in Google Scholar
  • 61 Peigne V, Azoulay E, Coquet I , et al. The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit Care 2013; 17 (6) R273
    CrossrefPubMedSuche in Google Scholar
  • 62 Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109 (22) 2698-2704
    CrossrefPubMedSuche in Google Scholar
  • 63 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M ; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (5) 1327-1330
    Thieme ConnectPubMedSuche in Google Scholar
  • 64 Levi M. Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol 2014; 36 (3) 228-236
    CrossrefPubMedSuche in Google Scholar